Stay updated on Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe study page for NCT03595683 now shows a 403 Forbidden error, replacing the expected content with an access-denied message and preventing access to the study details.SummaryDifference19%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe page revision was updated from v3.6.5 to v3.6.6, representing a new version of the ClinicalTrials.gov record. This revision does not change the study data or eligibility details.SummaryDifference0.1%

- Check53 days agoChange DetectedRevision bumped from v3.6.4 to v3.6.5, reflecting a minor page version update. It does not modify study content or user-facing information.SummaryDifference0.1%

- Check67 days agoChange DetectedThe page's version tag was updated from v3.6.3 to v3.6.4, signaling a minor platform update with no changes to the study details.SummaryDifference0.1%

- Check88 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3, indicating a small update to the page version.SummaryDifference0.1%

- Check95 days agoChange DetectedThe page now shows Revision: v3.6.2, replacing the previous v3.6.0, indicating an updated page version.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page.